Bay Area Biotech
Contributor since: 2013
Company: Bay Area Biotech
Latest Articles
With Approval Likely, Celldex Needs To Expand Commercial Capabilities
Arbutus Biopharma Is Currently In Second Place In The Race For An HBV Cure
Juno: A Leader In The Next Major Therapeutic Industry
Tobira: Undervalued With A Fast-Tracked NASH Compound
Acorda Therapeutics: Developing Innovative Therapies For Neurological Diseases
Lion Biotechnologies: Highlights
Cellectis: Finding Value In A Crowded CAR-T Space
Investing In Precision Oncology: Targeting NTRK Genomic Alterations
One Drug To Rule Them All: Medivation's Xtandi To Dominate Prostate Cancer Market
Trillium Therapeutics: A Preclinical Cancer Immunotherapy Company With A Promising Lead Compound
Mirati Therapeutics: Investing In A Piece Of The Precision Medicine Pie
Innate Pharma And The Role Of The Innate Immune System In Cancer Immunotherapy
Exelixis: Promise In The Pipeline
Optimistic For OncoMed's Future
DiaDexus: A Hearty Choice
Regulus Therapeutics: Strong Balance Sheet As It Moves Into Clinical Development
Supernus Secures Financing For CNS Pipeline Development
Lpath: The Leader In Lipidomics
OXiGENE's Oncology Drugs Have Run Their Course
Zohydro - Is There Enough Upside For Zogenix?
Osiris Therapeutics On The Brink: Products Failing To Deliver
Response Genetics' Competitors: Who To Watch, Who To Worry About
Incyte Pharmaceuticals Is Primed For A Run